Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company is rapidly advancing a product pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well- established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease. To learn more about Impel NeuroPharma, please visit our website at http://impelnp.com.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases w...
Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business Update
Jun 07, 2021
– Completed successful IPO raising approximately $80.0 million in gross proceeds –– NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 –– Strengthened commercial capabilities with expand...
Impel Neuropharma to Present Pivotal, Phase 3 Data From STOP-301 Study at The 63rd Annual Meeting of the American Headache Society
Jun 02, 2021
Data Will Evaluate Exploratory Efficacy Data from STOP-301 Study Evaluating INP104 Consistency of Response, Recurrence and Sustained Response Findings Also Highlight Safety and Tolerability Including Nausea and Nasal and Cardiovascular Safety...